Therefore, combining genetic knockdown of DYRK1A with a tau inhibitor might have synergistic effects on multiple aspects of AD pathology, including cognitive impairment, neuroinflammation, and Aβ/tau pathology. This evidence concerns the gene DYRK1A and Alzheimer disease.